Allergy Therapeutics PLC Stock
?
Your prediction
Allergy Therapeutics PLC Stock
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
Cons
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | 0.000% | -10.938% | -12.977% | 54.054% | -2.564% | 140.000% | -52.893% |
| Beximco Pharmaceuticals Ltd. GDR | 0.980% | 7.143% | -1.923% | 17.512% | 13.839% | -4.673% | -48.744% |
| Eledon Pharmaceuticals Inc. | 5.450% | 1.852% | -5.172% | -60.900% | 28.906% | -34.000% | -88.985% |
| SELLAS Life Sciences Group Inc | 5.190% | -2.373% | -9.663% | 144.066% | 8.818% | 1.782% | -62.406% |
News
AT&T's Secret Weapon for 2026: Why Fiber Could Drive Double-Digit EPS Growth
Telecom powerhouse AT&T (NYSE: T) is certainly a respectable company and a great dividend payer. But is it a growth stock? Hardly.
Except, for the foreseeable future, it's going to be putting up
AT&T Plans to Return $45 Billion to Shareholders. Is the Stock a Buy for 2026?
AT&T (NYSE: T) cut its dividend by nearly 50% in 2022. That move followed the spinoff of WarnerMedia, undoing what, in hindsight, proved to be a disastrous acquisition. Those two decisions set AT&T
Why AT&T Stock Surged This Week
Shares of AT&T (NYSE: T) jumped more than 10% this past week, according to data from S&P Global Market Intelligence.
The wireless carrier delivered an impressive quarterly financial report and


